RxDoctor Payments Data

Ryan Wisler

Internal Medicine · Montrose, CONPI 1922495001

Payments from drug & device makers

$285in general payments, 2019–2025

Across 16 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$108
  • Medtronic$61
  • Johnson & Johnson$42
  • Exact Sciences$21
  • Otsuka America Pharmaceutical, Inc.$18
  • AstraZeneca$13
  • plus $23 from 2 others

What the payments were for

  • Food & beverage$285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$285 in reported general payments places this provider in the 75th percentile of 1,430 internal medicine providers in Colorado.

See all internal medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$312,977
Medicare patients
500
Services billed
4,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide128$147,349
EliquisApixaban147$138,700
MounjaroTirzepatide82$89,969
Humira(Cf) PenAdalimumab12$84,306
WegovySemaglutide26$36,746
TrulicityDulaglutide35$32,848
XareltoRivaroxaban23$26,930
JardianceEmpagliflozin18$22,586
FarxigaDapagliflozin Propanediol23$22,251
Combivent RespimatIpratropium/Albuterol Sulfate15$16,495
LinzessLinaclotide19$14,825
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$13,913
QuliptaAtogepant12$12,474
Repatha SureclickEvolocumab12$11,789
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$11,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat$12$50,09449 claims
AstraZenecaFarxiga, Symbicort$13$29,69244 claims
Johnson & JohnsonXarelto$42$26,93023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,430 internal medicine providers in Colorado.

Other internal medicine in Montrose

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →